Employers Are Dropping GLP-1 Coverage for 2027: What to Check Before Open Enrollment Ends

The Business Group on Health's 2026 survey of 127 large employers — companies that together cover about 8.7 million people — found that the share covering GLP-1s for weight management fell from 72% in 2025 to 60% in 2026. On top of that, 14% of employers said they have dropped or plan to drop the coverage by 2027, up from 10% earlier in the year, and another 24% have never offered it at all.

Mercer's survey of 604 U.S. employers, run in April and May 2026, tells a similar story from a different angle: 6% of large employers dropped GLP-1 weight-loss coverage in 2026, another 5% plan to drop it or are considering it for 2027, and 27% have added or plan to add tighter utilization controls — things like higher BMI thresholds, required weight-management programs, or restrictions on which providers can prescribe.

The pullback isn't hypothetical. Starbucks announced it would stop covering GLP-1s prescribed for weight loss for benefits-eligible employees starting this October, while keeping coverage for diabetes and other approved conditions.

The short answer is cost at scale. Brand-name GLP-1 injectables list at roughly $1,000 to $1,500 a month, and employers have typically been paying 70% to 100% of that. With KFF estimating that about 1 in 8 U.S. adults is now taking a GLP-1, the math adds up fast: pharmacy now accounts for about a quarter of employers' total healthcare spend, and Mercer expects overall benefit costs to climb 6.7% in 2026 — past $18,500 per employee — with prescription drug costs rising around 9%.

Notably, most employers are not abandoning the category. In Mercer's data, nearly half of large employers still offer the coverage, and many of those cutting back are tightening eligibility rather than eliminating the benefit. But 48% of employers with 500 or more workers plan benefit changes for 2027 that will likely raise what employees pay out of pocket — so even if your drug stays covered, your share of the cost may grow.

Open enrollment is the moment to find out, because coverage changes usually take effect January 1 and plans are not required to flag them loudly. A few places to look: the Summary of Benefits and Coverage and the formulary (drug list) for the 2027 plan year, searching specifically for tirzepatide (Zepbound) and semaglutide (Wegovy); any letter from your pharmacy benefit manager about "formulary exclusions" taking effect in January; and new prior authorization or step therapy requirements, higher BMI cutoffs, or a requirement to enroll in a lifestyle program to keep the prescription.

If anything is unclear, ask HR or call the number on your insurance card and ask directly: "Is Zepbound (or Wegovy) covered for weight loss in 2027, and what are the requirements?" If your employer offers more than one plan, compare them on this point before you lock in — two plans from the same company can treat GLP-1s very differently.

Losing insurance coverage no longer means paying the full $1,000-plus list price. Both manufacturers now sell directly to self-pay patients: Eli Lilly's LillyDirect program offers Zepbound vials starting around $299 a month for the lowest dose and up to about $449 a month for higher maintenance doses, while Novo Nordisk's NovoCare pharmacy offers Wegovy to self-pay patients for about $349 a month, with the oral Wegovy pill introduced at lower price points — in the $149-a-month range for starting doses. Prices and program rules change often, so confirm current terms before you count on them.

Telehealth-based care is another path worth pricing out. Because visits are virtual and plans are built for cash-pay patients, programs like JoeyMed's tirzepatide program bundle the clinical oversight — provider evaluation, dose titration, side-effect management — at transparent monthly pricing, which can land well below what a suddenly uninsured brand prescription costs at the pharmacy counter.

A few things not to do: don't stop a GLP-1 abruptly without a plan, since weight regain after discontinuation is well documented — talk with your provider about tapering, maintenance options, or switching medications first. And be wary of gray-market or research-chemical versions of these drugs sold online without a prescription; the FDA has repeatedly flagged safety problems with unverified sources.

Whatever path keeps your treatment affordable, the medical basics don't change. GLP-1 medications commonly cause nausea, vomiting, constipation, and diarrhea — especially during dose increases — and anti-nausea support can help many patients stay on track through titration. These medications aren't right for everyone: people with a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, or who are pregnant or planning pregnancy need different options, which is why treatment should always start with a licensed provider reviewing your full history.

If your 2027 plan is dropping GLP-1 coverage — or piling on new hurdles — it's worth knowing your alternatives before January, not after your last covered refill. JoeyMed's licensed providers offer online consultations to review whether GLP-1 treatment fits your health profile, help you compare realistic self-pay options, and build a plan for continuing or starting treatment without insurance. Visit JoeyMed Weight Loss to complete a free online assessment and see transparent pricing — no insurance required, and no surprises when the plan year turns over.